Loading...
Market
Outcome of Blenrep's priority review by China's NMPA by December 31, 2025
2
American Society of Hematology•San Diego•California•Belantamab Mafodotin•China•National Medical Products Administration•NMPA•Blenrep
Resolution / Starting Odds
Full Approval • 25%
Conditional Approval • 25%
Rejection • 25%
Request for More Data • 25%
China's NMPA official announcements
Story
GSK's Blenrep Reduces Death Risk by 42% in Blood Cancer Trial, Gains Priority Review in China
Dec 9, 2024, 06:36 PM
GSK has presented positive results from a Phase III clinical trial at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California. The trial evaluated the company's blood cancer treatment, Belantamab Mafodotin (Blenrep), showing a significant reduction in the risk of death by 42% for patients with relapsed or refractory multiple myeloma. This outcome suggests a potential revival for the drug, which was withdrawn from the market two years ago. Additionally, China’s National Medical Products Administration (NMPA) has accepted GSK's application for a combination therapy involving Blenrep, granting it priority review status for relapsed/refractory multiple myeloma, supported by the DREAMM-7 trial results.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved • 25%
Not Approved • 25%
Approval Pending • 25%
Withdrawn • 25%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
Yes • 50%
No • 50%
